Multiple domestic pharmaceutical companies launched generic semaglutide on Saturday, a day after the drug's patent expired in India, with prices falling by as much as 90% from the branded version, ...

https://www.thehindubusinessline.com/companies/generic-versions-of-novo-nordisks-semaglutide-begin-to-flow-priced-50-80-lower-than-the-innovator/article70769849.ece ...

MUMBAI – A deluge of weight-loss drugs is set to transform the global fight against obesity, as India prepares to unleash low-cost generic versions of injections like Ozempic after a key patent ...

At least a dozen large Indian drugmakers are set to roll out copies of Novo Nordisk A/S’s blockbuster weight-loss drugs as soon as the patent expires Friday, crashing prices in the country with the ...

India's pharma industry is ready to flex its generics muscle as the patent for a key ingredient of blockbuster weight-loss drugs expires today. Pharmarack estimates India’s weight-loss drug market to ...

With patents expiring today in India for Novo Nordisk’s popular diabetes and obesity drugs Ozempic and Wegovy, more than 40 generic drug makers are expected to begin launching their cheaper versions ...

Tensions in the Strait of Hormuz are raising alarms about the stability of global pharmaceutical supply chains, with potential implications for the U.S. generic drug market, which relies heavily on ...

The FDA has approved a generic version of fluticasone propionate (marketed as Flovent HFA), according to a statement issued on March 3. The approval extends the accessibility of the medication, ...

Over the last year, Sanofi has been busy reshaping itself to focus more on innovative drugs, including selling a controlling stake in its former consumer business and using those proceeds to strike a ...